Human botulism (type F)—A rare type

Green, Jacob; Spear, Harold C.; Brinson, Robert R.

doi:10.1016/0002-9343(83)90424-2

Cited by 18 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though serotypes A, B, and E are most associated with botulism outbreaks in humans, type F has also been diagnosed [37][38][39]. A separate monovalent toxoid vaccine against BoNTF [40] was manufactured for the U.S. Army by Porton Products Limited in cooperation with the United Kingdom Governments Center for Applied Microbiology and Research (CAMR) in 1990.…”

Section: Bont Toxoid Vaccinesmentioning

confidence: 99%

Development of vaccines for prevention of botulism

2000

View full text Add to dashboard Cite

-Botulism is a potentially lethal disease caused by one of seven homologous neurotoxic proteins usually produced by the bacterium, Clostridium botulinum. This neuromuscular disorder occurs through an exquisite series of molecular events, ultimately ending with the arrest of acetylcholine release and hence, flaccid paralysis. The development of vaccines that protect against botulism dates back to the 1940s. Currently, a pentavalent vaccine that protects against BoNT serotypes A-E and a separate monovalent vaccine that protects against BoNT serotype F are available as Investigational New Drugs. However, due to the numerous shortcomings associated with the toxoid vaccines, several groups have efforts towards developing next-generation vaccines. Identifying a synthetic peptide that harbors a neutralizing epitope is one approach to a BoNT vaccine, while another employs the use of a Venezuelan equine encephalitis virus replicon vector to produce protective antigens in vivo against BoNT. The strategy used in our laboratory is to design synthetic genes encoding non-toxic, carboxy-terminal fragments of the C. botulinum neurotoxins (rBoNT(H C )). The gene products are expressed in the yeast, Pichia pastoris, and purified to greater than 98% with yields typically ranging from 200-500 mg per kg of wet cells. Protective immunity to the purified products against high-level challenges of neurotoxin is elicited in mice and in non-human primates. A pre-Investigational New Drug meeting was held with the Food and Drug Administration, and the next milestone for the vaccine candidates will be clinical trials. © 2000 Société française de biochimie et biologie moléculaire / Éditions scientifiques et médicales Elsevier SAS botulinum neurotoxin / vaccine / C-fragment / purification / efficacy

show abstract

Section: Bont Toxoid Vaccinesmentioning

confidence: 99%

Development of vaccines for prevention of botulism

2000

View full text Add to dashboard Cite

show abstract

“…Currently, a pentavalent toxoid vaccine against serotypes A-E (18 -21), available under Investigational New Drug (IND) status, is used to immunize specific populations of at-risk individuals, i.e., scientists and health care providers who handle BoNT and our armed forces, who may be subjected to weaponized forms of the toxin. Though serotypes A, B, and E are most associated with botulism outbreaks in humans, type F has also been diagnosed (22)(23)(24). A separate monovalent toxoid vaccine against BoNTF is available under IND status (25).…”

mentioning

confidence: 99%

Fermentation, Purification, and Efficacy of a Recombinant Vaccine Candidate against Botulinum Neurotoxin Type F from Pichia pastoris

Byrne

Titball²,

Holley³

et al. 2000

Protein Expression and Purification

View full text Add to dashboard Cite

“…3 , 4 Human disease from the toxin produced by Clostridium butyricum and Clostridium baratii has also been reported in case series. 4 , 5 , 6 , 7 , 8 According to the CDC's Botulism Surveillance Summary 2016, 9 there were 205 confirmed and 10 probable cases of human botulism that year. Distribution of the major types of botulism such as infantile, food, and wound are 73%, 14%, and 12%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Adult Intestinal Botulism: A Rare Presentation in an Immunocompromised Patient With Short Bowel Syndrome

Guru

Becker

Stephens

et al. 2018

Mayo Clinic Proceedings: Innovations, Quality & Outcomes

View full text Add to dashboard Cite

The cholinergic heat-labile neurotoxin produced by Clostridium species is primarily responsible for the clinical manifestations of botulism. The classic phenotypic presentation of botulism consists of subacute descending flaccid paralysis with intact sensory function. Traditionally, it is classified into 3 main forms (foodborne, wound-related, and infantile) on the basis of primary site of toxin entry into the human nervous system. Toxemia is the common pathophysiology in all forms of botulism. Adult intestinal toxemia botulism is an extremely rare form of the disease with pathogenesis similar to that of infant-type botulism. Symptomatic adults usually have an anatomic abnormality in the gastrointestinal tract leading to changes in normal gut flora. The current case is an addition to the growing literature on this unusual clinical variant of botulism.

show abstract

Human botulism (type F)—A rare type

Cited by 18 publications

References 18 publications

Development of vaccines for prevention of botulism

Development of vaccines for prevention of botulism

Fermentation, Purification, and Efficacy of a Recombinant Vaccine Candidate against Botulinum Neurotoxin Type F from Pichia pastoris

Adult Intestinal Botulism: A Rare Presentation in an Immunocompromised Patient With Short Bowel Syndrome

Contact Info

Product

Resources

About